ArticleMarine drugs2014
The protective effect of fucoidan in rats with streptozotocin-induced diabetic nephropathy.
Article in Marine drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Fucoidan Treatment Improves Diabetic Hyperglycemia and Dyslipidemia in Rodents: A Systematic Review and Meta-Analysis.Nutrients · 2026Pooled it
- Micro RNA Expression after Ingestion of Fucoidan; A Clinical Study.Marine drugs · 2020Trial
- Multidimensional mechanisms of natural products in modulating metabolic dysfunction-associated kidney disease: recent advances and future perspectives.Frontiers in pharmacology · 2026Review
- Fucoidan as a renal protectant: mechanistic insights and therapeutic implications of endothelial glycocalyx targeting.Frontiers in pharmacology · 2026Review
- Tiliroside protects against diabetic nephropathy in streptozotocin-induced diabetes rats by attenuating oxidative stress and inflammation.World journal of diabetes · 2024Article
- Article
- The Emerging Evidence for a Protective Role of Fucoidan fromMarine drugs · 2022Article
- Nephroprotective role of nanoencapsulated Tinospora cordifolia (Willd.) using polylactic acid nanoparticles in streptozotocin-induced diabetic nephropathy rats.IET nanobiotechnology · 2021Article
- RIPK3-Mediated Necroptosis in Diabetic Cardiomyopathy Requires CaMKII Activation.Oxidative medicine and cellular longevity · 2021Article
- Ferroptosis Is a Potential Novel Diagnostic and Therapeutic Target for Patients With Cardiomyopathy.Frontiers in cell and developmental biology · 2021Review
- Pharmacokinetics of Marine-Derived Drugs.Marine drugs · 2020Review
- Comparative Study of Fucoidan fromMarine drugs · 2020Article
- Distinct Types of Cell Death and the Implication in Diabetic Cardiomyopathy.Frontiers in pharmacology · 2020Review
- Fucoidan Ameliorates Oxidative Stress, Inflammation, DNA Damage, and Hepatorenal Injuries in Diabetic Rats Intoxicated with Aflatoxin BOxidative medicine and cellular longevity · 2020Article
- Fucoidan alleviates microcystin-LR-induced hepatic, renal, and cardiac oxidative stress and inflammatory injuries in mice.Environmental science and pollution research international · 2020Article
- Fucoidan Structure and Activity in Relation to Anti-Cancer Mechanisms.Marine drugs · 2019Review
- Pharmacokinetic and Tissue Distribution of Fucoidan fromMarine drugs · 2018Article
- Fucoidan Rescues p-Cresol-Induced Cellular Senescence in Mesenchymal Stem Cells via FAK-Akt-TWIST Axis.Marine drugs · 2018Article
- Fucoidan elevates surface organic cation transporter 2 expression via upregulation of protein kinase A in uric acid nephropathy.Experimental and therapeutic medicine · 2017Article
- Protective effect of berberine on renal fibrosis caused by diabetic nephropathy.Molecular medicine reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic nephropathy (DN) has long been recognized as the leading cause of end-stage renal disease, but the efficacy of available strategies for the prevention of DN remains poor. The aim of this study was to investigate the possible beneficial effects of fucoidan (FPS) in streptozotocin (STZ)-induced diabetes in rats. Wistar rats were made diabetic by injection of STZ after removal of the right kidney. FPS was administered to these diabetic rats for 10 weeks. Body weight, physical activity, renal function, and renal morphometry were measured after 10 weeks of treatment. In the FPS-treated group, the levels of blood glucose, BUN, Ccr and Ucr decreased significantly, and microalbumin, serum insulin and the β2-MG content increased significantly. Moreover, the FPS-treated group showed improvements in renal morphometry. In summary, FPS can ameliorate the metabolic abnormalities of diabetic rats and delay the progression of diabetic renal complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.